

Presentation	Supplier Name	Market Segment	HPV																	
			2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Bivalent Human Papilloma Virus (Types 16 and 18) vaccine - 1 dose vial	Xiamen Innovax Biotech Co (China)	Gavi73 ¹															\$2.9000	\$2.9000	\$2.9000	\$2.9000
Bivalent Human Papilloma Virus (Types 16 and 18) vaccine - 2 dose vial	GlaxoSmithKline Biologicals (Belgium)	Gavi73 ²						\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$5.1800	\$5.1800	\$5.1800	\$5.1800
	GlaxoSmithKline Biologicals (Belgium)	GNI per capita < \$3,995 ³													\$10.2500 - \$11.4000	\$10.2500 - \$11.4000	\$10.2500 - \$11.4000	\$10.2500	\$10.2500	\$10.2500
	GlaxoSmithKline Biologicals (Belgium)	GNI per capita > \$3,995 ³													\$14.1400	\$14.1400	\$14.1400	\$14.1400	\$14.1400	\$14.1400
Quadravalent Human Papilloma Virus (Types 6, 11, 16 and 18) vaccine - 1 dose vial	Merck Sharpe and Dome Corp (USA)	Gavi73 ²						\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000
	Merck Sharpe and Dome Corp (USA)	MICs ⁴										\$13.4000	\$13.4000	\$13.4000 - \$25.0000	\$13.4000 - \$25.0000	\$13.5000 - \$26.7500				

Data shows awarded price per dose in US\$ per product per supplier per calendar year, based on supply agreement.

Prices displayed are in response to tenders with FCA incoterms.

¹Prices apply to Gavi-eligible and transitioned countries

²Prices apply to Gavi-eligible and transitioning countries as listed on Gavi's website at https://www.gavi.org/types-support/sustainability/eligibility and https://www.gavi.org/types-support/sustainability/transition

³Prices are applicable to the following non-Gavi Middle-Income Countries: Pacific Island Countries and Cape Verde

⁴Prices are applicable to the following non-Gavi Middle-Income Countries: Botswana, Maldives, Morocco, Seychelles and Turkmenistan. Last updated 6th February 2024.